We identify three MEK inhibitors in the osteosarcoma cell viability screen: Trametinib is a selective allosteric inhibitor of MEK1/2 designed to treat tumors with overactive MEK-ERK pathway, which is found in tumors with B-Raf mutations [40]. This evidence concerns the gene BRAF and osteosarcoma.